A phase I study of the antimetabolite (E)-2'-fluoromethylene-2'-deoxycytidine (MDL 101,731) administered as a twice-weekly infusion

Cancer Journal

Volumn 6, Issue 5, 2000, Pages 309-315

  Burtness, B ^a   Belker, M ^a   Stoltz, M ^a   Peccerillo, K M ^a   Lamb, L A ^a   Chmael, S E ^a   McKeon, A ^a   Clark, M B ^a   Winship, J ^a   Marsh, J C ^a   Pizzorno, G ^a   DeVita V T , Jr ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Chemotherapy; Epithelial malignancies; Ribonucleotide reductase

Indexed keywords

TEZACITABINE;

ADULT; AGED; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CELL PROLIFERATION; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DNA DAMAGE; DOSE RESPONSE; FEVER; HUMAN; LEUKOPENIA; MUCOSA INFLAMMATION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RECTUM CANCER; THROMBOCYTOPENIA; TUMOR XENOGRAFT;

ADULT; AGED; ANTINEOPLASTIC AGENTS; DEOXYCYTIDINE; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; TIME FACTORS; TREATMENT OUTCOME;

EID: 0033764706     PISSN: 15289117     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Ribonucleotide reductase and cell proliferation
2. Ribonucleotide reductase R2 component is a novel malignancy determinant that cooperates with activated oncogenes to determine transformation and malignant potential
3. Overexpression of transfected human ribonudeotide reductase M2 subunit in human cancer cells enhances their invasive potential
4. DNA damage induction of ribonucleotide reductase
5. Alterations in the activity and regulation of mammalian ribonucleotide reductase by chlorambucil, a DNA damaging agent
6. Expression of ribonucleotide reductase after ionizing radiation in human cervical carcinoma cells
7. Regulation and drug resistance mechanisms of mammalian ribonucleotide reductase, and the significance to DNA synthesis
8. 3 cells
9. A phase I evaluation of MDL 101,731 administered every 21 days, utilizing the modified continual reassessment method for dose escalation
10. Animal toxicology for early clinical trials with anticancer agents
11. Variations of the phosphorylation of 1-β-D-arabinofuranosylcytosine (Ara-C) in human myeloid leukemia cells related to the cell cycles
12. Changes in messenger RNA levels for the subunits of ribonucleotide reductase during the cell cycle of leukemia L1210 cells
13. Differential incorporation of ara-C, gemcitabine, and fludarabine into replicating and repairing DNA in proliferating human leukemia cells